Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news

PET/MRI provides new insights into knee osteoarthritis
PET/MRI has identified which compartments of the knee may be the best target...Read more on AuntMinnie.comRelated Reading: PET/MRI superior to MRI for diagnosing prostate cancer ECR: Hypmed project develops affordable PET/MRI for breast scans PET/MRI appears safe for pregnant women PET/MRI can improve diagnosis of peritoneal cancer PET/MRI proves TNF blockers effective for ankylosing spondylitis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 19, 2022 Category: Radiology Source Type: news

New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomy
(MedPage Today) -- The presence of serous tubal intraepithelial carcinoma (STIC) at the time of risk-reducing salpingo-oophorectomy (RRSO) significantly increased the risk of peritoneal carcinomatosis (PC) in BRCA1/2 mutation carriers, a large... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - April 5, 2022 Category: OBGYN Source Type: news

PET/MRI superior to MRI for diagnosing prostate cancer
PET/MRI imaging with an experimental prostate-specific membrane antigen (PSMA...Read more on AuntMinnie.comRelated Reading: PET improves prostate cancer survival predictions FDA approves Lu-177 PSMA-617 for prostate cancer treatment PET/MRI appears safe for pregnant women PET/MRI can improve diagnosis of peritoneal cancer How can the clinical potential of PET/MRI be unlocked? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 31, 2022 Category: Radiology Source Type: news

ECR: Hypmed project develops affordable PET/MRI for breast scans
A European research project called Hypmed is developing a more affordable versio...Read more on AuntMinnie.comRelated Reading: ECR: Breast MRI tops contrast mammo for risk-based screening ECR: How can imaging screen for COVID damage to kidneys? ECR: What will it be like to be a radiologist in 2030? PET/MRI appears safe for pregnant women PET/MRI can improve diagnosis of peritoneal cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 4, 2022 Category: Radiology Source Type: news

ECR: Hypmed project develops affordable PET/MRI for breast imaging
A European research project called Hypmed is developing a more affordable versio...Read more on AuntMinnie.comRelated Reading: ECR: Breast MRI tops contrast mammo for risk-based screening ECR: How can imaging screen for COVID damage to kidneys? ECR: What will it be like to be a radiologist in 2030? PET/MRI appears safe for pregnant women PET/MRI can improve diagnosis of peritoneal cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 4, 2022 Category: Radiology Source Type: news

Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a selective poly-ADP ribose polymerase (PARP) inhibitor, in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without specific homologous recombination repair (HRR) gene alterations. At the final analysis for radiographic progression-free survival (rPFS), the treatment combination of niraparib and abiraterone acetate plus prednisone de...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

PET/MRI can improve diagnosis of peritoneal cancer
PET/MRI performs better than standard imaging for diagnosing cancer that ha...Read more on AuntMinnie.comRelated Reading: PET/MRI proves TNF blockers effective for ankylosing spondylitis PET/MRI proves valuable in difficult epilepsy cases How can the clinical potential of PET/MRI be unlocked? PET/MRI bests MRI alone for detecting recurrent prostate cancer When will PET/MRI live up to its promise? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 10, 2021 Category: Radiology Source Type: news

How Can You Prevent Peritoneal Cancer?
Title: How Can You Prevent Peritoneal Cancer?Category: Diseases and ConditionsCreated: 9/22/2021 12:00:00 AMLast Editorial Review: 9/22/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 22, 2021 Category: Cancer & Oncology Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers
Hematology / Oncology Drug Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Aging cells in abdominal fluid cause increased peritoneal dissemination of gastric cancer
(Kumamoto University) Through an analysis of cell fractions from malignant ascites, cellular senescence of cancer-associated fibroblasts (CAFs) has been found to be important in the progression of gastric cancer peritoneal dissemination foci. This understanding should enable the development of new treatments for peritoneal cancer dissemination by targeting cancer cells at dissemination sites and CAFs in patients with peritoneal dissemination. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 23, 2021 Category: Biology Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Single-cell analysis of metastatic gastric cancer finds diverse tumor cell populations associated with patient outcomes
(University of Texas M. D. Anderson Cancer Center) Researchers from The University of Texas MD Anderson Cancer Center who profiled more than 45,000 individual cells from patients with peritoneal carcinomatosis (PC), a specific form of metastatic gastric cancer, defined the extensive cellular heterogeneity and identified two distinct subtypes correlated with patient survival. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 4, 2021 Category: International Medicine & Public Health Source Type: news